CVRx, Inc.

CVRX

Exchange: Nasdaq
Industry: Surgical & Medical Instruments & Apparatus
SEC CIK: 0001235912

SEC filings (opens in a new tab)

No open-market purchases or sales by CVRx, Inc. insiders were filed in the last 90 days; 87 institutions reported holding it in 13F filings for Q2 2026, worth $78.7M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 11, 2026: $19.9M
Insider buysOpen market, last 90 days: 0
Insider sellsOpen market, last 90 days: 0
13F holdersQ2 2026, −10 vs. previous quarter: 87
13F valueReported value at the end of Q2 2026: $78.7M
Superinvestors holdingAt the end of Q2 2026: 0

Price chart

Chart by TradingView (opens in a new tab)

Financials

See financial statements

From SEC filings, in USD.

Revenue, FY2025: $56.7M; +10.4% year over year
Net income, FY2025: -$53.3M; No comparable prior period
Free cash flow, FY2025: -$40.8M; No comparable prior period
Revenue, Q3 FY2026: $13.8M; −5.8% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $53.3M (94.1% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest: 1.82M; Shares sold short
Change: −318.3K; −14.9% vs. previous
Days to cover: 5.33; At average daily volume

Superinvestors holding CVRX, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding CVRX at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by CVRx, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Aug 13, 2026 (view filing)8:18 PM ET	Aug 13	Same day	Binkowski BrentCHIEF OPERATING OFFICER	PPurchase	+26.2K	$2.91	+$76.4K	+86.6%56.5K after
Aug 13, 2026 (view filing)4:26 PM ET	Aug 12	1 day	Binkowski BrentCHIEF OPERATING OFFICER	SSale	−1.31K	$2.55	−$3.34K	−4.1%30.3K after	10b5-1
Mar 16, 2026 (view filing)	Mar 2	14 daysLate	Adamson Philip B.Chief Medical Officer	SSale	−1.26K	$7.90	−$9.97K	−2.0%61.6K after	10b5-1
Mar 3, 2026 (view filing)	Mar 2	1 day	John Robert AllenChief Revenue Officer	SSale	−3.96K	$7.90	−$31.3K	−4.4%86.0K after	10b5-1
Mar 3, 2026 (view filing)	Mar 2	1 day	Verrastro PaulCHIEF MKTG & STRAT OFFICER	SSale	−1.28K	$7.90	−$10.1K	−2.1%60.6K after	10b5-1
Mar 3, 2026 (view filing)	Mar 2	1 day	Oasheim JaredCHIEF FINANCIAL OFFICER	SSale	−1.74K	$7.90	−$13.8K	−1.8%96.7K after	10b5-1
Mar 3, 2026 (view filing)	Mar 2	1 day	Hykes KevinPRES & CEO	SSale	−7.76K	$7.90	−$61.3K	−2.7%284.2K after	10b5-1
Feb 23, 2026 (view filing)	Feb 20	3 days	Jain Mudit K.Director	PPurchase	+46.8K	$6.36	+$297.6K	+5.0%980.2K after
Feb 18, 2026 (view filing)	Feb 18	Same day	Jain Mudit K.Director	PPurchase	+600	$4.64	+$2.78K	+11.9%5.65K after
Jan 8, 2026 (view filing)4:05 PM ET	Nov 25-26, 2025	44 days	Johnson & Johnson and 1 other10% Owner	SSale	−22.3K	$10.03	−$224.0K	−0.6%4.02M after	Amended2 lots

Top 10 13F holders, Q2 2026

See all 87 holders

The largest institutional positions in CVRx, Inc. at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding CVRX in Q2 2026
Institution	Shares	Value	% of portfolio	Change in shares	Action
Johnson & Johnson	4,024,861	$20.7M	2.59%	00.0%	Unchanged
NEA Management Company, LLC	1,954,440	$10.0M	0.63%	−71,643−3.5%	Reduced
BlackRock, Inc.	1,245,459	$6.40M	0.00%	+218,900+21.3%	Added
Royal Bank of Canada	1,233,212	$6.34M	0.00%	+526,262+74.4%	Added
GSK plc	1,007,583	$5.18M	0.86%	00.0%	Unchanged
Vanguard Capital Management LLC	910,576	$4.68M	0.00%	−734−0.1%	Reduced
Silvercrest Asset Management Group LLC	878,109	$4.51M	0.03%	+306,088+53.5%	Added
Geode Capital Management, LLC	440,786	$2.27M	0.00%	+13,714+3.2%	Added
PFM Health Sciences, LP	369,572	$1.90M	0.16%	+369,572	New
State Street Corp	366,352	$1.88M	0.00%	+15,804+4.5%	Added

Holders of 5% or more of CVRX

See all 3 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of CVRx, Inc..

Largest holders of CVRX from 13D and 13G filings
Holder	Latest form	Stake	Change	First filed	Latest filing	Filing
Johnson & Johnson	13G/A	15.40%4.02M shares	–	Feb 7, 20224 filings	Jan 12, 2026	SEC
New Enterprise Associates 10 L P	13D/A	7.80%2.03M shares	–	Jul 15, 20213 filings	Feb 20, 2025	SEC
Vensana Capital I GP, LLC	13G/A	7.20%1.76M shares	–	Feb 10, 20224 filings	Feb 6, 2025	SEC